Literature DB >> 10585151

Predictors for heparin resistance in patients undergoing coronary artery bypass grafting.

M Ranucci1, G Isgrò, A Cazzaniga, G Soro, L Menicanti, A Frigiola.   

Abstract

Heparin resistance (HR) is a common event in cardiac operations. At present, no clear recognition of the risk factors for HR has been reached. The aim of this study was to determine a predictive model for HR, based on the preoperative patient's profile. Two hundred consecutive patients scheduled for elective coronary artery bypass operations were enrolled in a prospective trial. Demographics, type of preoperative anticoagulation therapy and preoperative coagulation profile were collected and statistically analysed with respect to the evidence of a HR. Heparin resistance was defined as at least one activated clotting time < 400 s after heparinization and/or the need for purified antithrombin III (AT-III) administration. With a multivariate analysis we could identify five predictors for HR: AT-III < or = 60%; preoperative subcutaneous heparin therapy; intravenous heparin therapy; platelet count > or = 300000 cells/mm3; age > or = 65 years. We conclude that HR is a predictable event. In the presence of all the risk factors, the likelihood of HR is 99%; in the absence of all of them, it is 10%. Predicting HR allows us to apply many possible therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585151     DOI: 10.1177/026765919901400606

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  18 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Sudden Thrombosis in Coronary Artery Bypass Grafting Surgery.

Authors:  Bin Cheng; Jun-Sheng Mu; Jian-Qun Zhang; Ping Bo
Journal:  Chin Med J (Engl)       Date:  2015-10-20       Impact factor: 2.628

Review 3.  Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations.

Authors:  Sean Garvin; Daniel Fitzgerald; Jochen D Muehlschlegel; Tjörvi E Perry; Amanda A Fox; Stanton K Shernan; Charles D Collard; Sary Aranki; Simon C Body
Journal:  Anesth Analg       Date:  2010-02-08       Impact factor: 5.108

4.  Four cases of thrombotic events associated with neuro-endovascular therapy: heparin resistance and aspirin resistance.

Authors:  K Naito; H Nagashima; F Oya; J Koyama
Journal:  Interv Neuroradiol       Date:  2007-06-27       Impact factor: 1.610

5.  Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study.

Authors:  Jacob T Beyer; Kelly E Schoeppler; Giorgio Zanotti; Gregory M Weiss; Scott W Mueller; Robert MacLaren; Douglas N Fish; Tyree H Kiser
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-13       Impact factor: 2.389

6.  Acute normovolemic hemodilution does not reduce antithrombin concentration for cardiac surgery.

Authors:  Matthew Dean Linden; Mark Schneider; Wendy Naomi Erber
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

Review 7.  [Heparin resistance and antithrombin deficiency].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2009-06-16

8.  Successful anticoagulation with fresh frozen plasma for cardiopulmonary bypass in a patient with heparin resistance: a cautionary tale.

Authors:  Omar Badrin; Suana Kushairi; Zuhrah Zakaria; Anand Sachithanandan
Journal:  BMJ Case Rep       Date:  2013-04-29

9.  The evaluations of frequency distribution heparin resistance during coronary artery bypass graft.

Authors:  Kaivan Bagheri; Azim Honarmand; Mohammadreza Safavi; Parviz Kashefi; Lale Sayadi; Leila Mohammadinia
Journal:  Adv Biomed Res       Date:  2014-01-27

10.  Massive atrial myxoma requiring emergency cardiopulmonary bypass in a patient with heparin resistance.

Authors:  E Houston; P Moran; D Mayhew
Journal:  Anaesth Rep       Date:  2020-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.